IL17A and psoriasis: Simultaneous blockade of both cytokines, which are key mediators of the Th17-dependent inflammatory axis, may lead to more effective suppression of inflammation than neutralising IL-17A alone in patients with moderate to severe psoriasis [152,153,154].